In that respect, it has been demonstrated that the oncogenic KRAS mutations are associated to an increased production of the GM-CSF, which causes the expansion of immunosuppressive Gr1+CD11b+ myeloid cells in mouse PC models; GM-CSF inhibition, in turn, could prevent MDSC recruitment and tumor development [251]. The gene discussed is CSF2; the disease is pachyonychia congenita.